Savara Inc. (NASDAQ:SVRA) Receives $5.60 Average Target Price from Analysts

Shares of Savara Inc. (NASDAQ:SVRA) have earned a consensus rating of “Moderate Buy” from the five brokerages that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $5.60.

SVRA has been the subject of a number of recent research reports. Wells Fargo & Company decreased their price objective on Savara from $8.00 to $7.00 and set an “overweight” rating for the company in a report on Wednesday, May 28th. Guggenheim reiterated a “buy” rating and set a $8.00 price target (down previously from $9.00) on shares of Savara in a report on Wednesday, May 28th. HC Wainwright cut Savara from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $6.00 to $2.00 in a research note on Thursday, May 29th. Finally, Evercore ISI cut their price objective on shares of Savara from $3.00 to $2.00 and set an “in-line” rating on the stock in a report on Wednesday, May 28th.

Insider Activity at Savara

In other Savara news, Director Richard J. Hawkins purchased 48,225 shares of the company’s stock in a transaction that occurred on Friday, June 20th. The shares were acquired at an average cost of $2.04 per share, for a total transaction of $98,379.00. Following the completion of the acquisition, the director owned 115,466 shares of the company’s stock, valued at $235,550.64. The trade was a 71.72% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 5.33% of the company’s stock.

Institutional Investors Weigh In On Savara

Several large investors have recently made changes to their positions in the business. Cibc World Markets Corp purchased a new position in shares of Savara in the 4th quarter worth about $33,000. XTX Topco Ltd bought a new stake in Savara in the fourth quarter worth about $34,000. Ameriprise Financial Inc. purchased a new position in Savara in the fourth quarter valued at about $37,000. KLP Kapitalforvaltning AS bought a new position in shares of Savara during the 4th quarter valued at approximately $41,000. Finally, Hsbc Holdings PLC bought a new position in shares of Savara during the 4th quarter valued at approximately $48,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Stock Performance

Shares of SVRA stock opened at $2.58 on Friday. The company has a current ratio of 14.91, a quick ratio of 14.91 and a debt-to-equity ratio of 0.20. The firm has a fifty day simple moving average of $2.35 and a two-hundred day simple moving average of $2.67. Savara has a 12 month low of $1.89 and a 12 month high of $4.74. The firm has a market capitalization of $445.93 million, a PE ratio of -5.37 and a beta of 0.31.

Savara (NASDAQ:SVRA) last posted its earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). Analysts forecast that Savara will post -0.45 EPS for the current fiscal year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.